Neuroendocrine differentiation and cell proliferation markers in prostatic adenocarcinoma in a group of patients with PSA normal vs. elevated;Diferenciación neuroendocrina y marcadores de proliferación celular en adenocarcinoma de próstata en un grupo de casos con antígeno prostático específico normal vs elevado

Gaceta Medica de Mexico

Volumn 142, Issue 6, 2006, Pages 441-446

  Feria Bernal, Guillermo ^a   García González, Víctor Manuel ^a   Figueroa Granados, Víctor ^a   Martínez Benítez, Braulio ^a   Uribe Uribe, Norma Ofelia ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Neuroendocrine differentiation; Proliferation markers; Specific prostatic antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CELL PROLIFERATION; COMPARATIVE STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMORS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846987250     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Aihara, M, Scardino P, Truong T, Wheeler T, Goad J, Yang G, et al. The frequency of apoptosis correlates with the prognosis of Gleason Garde 3 adenocarcinoma of the prostate. Cancer 1995;75(2):522-529.
2. Becker C, Piironen T, Pettersson K, Björk T, Wojno K, Oesterling J, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000;163:311-316.
3. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88(11):2590-2597.
4. Cherry J, Mordente J, Chapman J, Choudhury M, Tazaki H, Mallouh C, et al. Analysis of Cathepsin D forms and their clinical implications in human prostate cancer. J Urol 1998;160(6):2223-2228.
5. Bostwick D, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh E, et al. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002;168:1204-1211.
6. Burchardt T, Burchardt M, Chen MW, Cao Y, De la Taille A, Shabsigh a, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805.
7. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch M and Gasser T. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998;160(2):406-410.
8. Dénes F, Brito A, Dos-Santos A. Subcutaneous and testicular metastasis from prostatic adenocarcinoma with neuroendocrine differentiation. Braz J Urol 2001;27(1):52-54.
9. di Sant'Agnese PA. Divergent neuroendocrine differentiation in prostatic carcinoma. Semin Diagn Pathol 2000;17(2):149-161.
10. Gohji K, Kitazawa S, Tamada H, Katsuoka Y and Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165:1033-1036.
11. Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen T, Määttänen L, et al. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001;165:1569-1574.
12. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N and Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002(2);167:512-515.
13. st century. J Urol 2000;163:828.
14. Karazanashvili G and Per-Anders Abrahamsson. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003;169:445-457.
15. Lehrer S, Diamond E, Stone N, Droller M and Stock R. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol 2002;168:2431-2433.
16. Wehbi NK, Dugger A, Bonner R, Pitha J, Hurst R and Hemstreet G III. Pan-Cadherin as a high level phenotypic biomarker for prostate cancer. J Urol 2002;167:2215-2221.
17. Yashi M, Muraishi O, Tokue A. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide. BJU Int 2001;88(3):306-308.
18. Yang, G, Stapleton A, Wheeler T, Truog L, Timmer T, Scaedino P, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Research 1996;2:399-401.
19. Epstein J. Pathology of Prostatic Neoplasia. In: Campbell's Urology, 8ed. Edited by P. C. Walsh, A.B. Retik, E.D. Vaughan and A.J. Wein. Philadelphia: W.B. Saunders Co., vol. 4, capt 86, pp. 3025-3037, 2002.
20. Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000;163:1739-1742.